RecruitingNCT03648814Updated Aug 21, 2025

Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

An interventional study of Intracameral injection and Intravitreal injection in Glaucoma, Neovascular and Vascular Endothelial Growth Factor Overexpression, sponsored by Prince of Songkla University. Recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Prince of Songkla University · Not applicable, Interventional, and Treatment

From the registry’s dates

Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
Started Aug 2018; still recruiting 8 years 2 months later.

Phase: Not applicable
Study type: Interventional
Enrollment: 40
Allocation: Randomized
Ages: 18 Years and older
Sex: All

Study summary

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Read the detailed description

The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma

Conditions studied

Glaucoma, Neovascular
Vascular Endothelial Growth Factor Overexpression

Browse trials for

Glaucoma, Neovascular 36

Keywords

Neovascular glaucoma

In context

Glaucoma, Neovascular

36 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 30 interventional studies indexed under Glaucoma, Neovascular.

Browse Glaucoma, Neovascular studies →

Lead sponsor

Prince of Songkla University is the lead sponsor of 112 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Diagnosis of neovascular glaucoma
The patients having IOP > 21 mmHg, having the indication for trabeculectomy
The patients' age of at least 18-year-old
The patients having visual potential at least hand motion.
Present of NVI or NVA.
Willing and able to provide informed consent to participate in the study
Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits

Exclusion criteria

Exclusion Criteria:

One eye patient
Patients having severe corneal edema or total hyphema obscure NVI or NVA view.
Cannot obtain endothelial cell count.
History of bevacizumab or fluorescence dye allergy.
Active infectious ocular disease including endophthalmitis and corneal ulcer
History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension
Has or planning to be pregnant or breastfeeding

Study design

Phase: Not applicable
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Single (Outcomes assessor)
Enrollment: 40 participants (estimated)

Study arms

Experimental
Intracameral injection
Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection
Procedure: Intracameral injection
Experimental
Intravitreal injection
Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection
Procedure: Intravitreal injection

Interventions

ProcedureIntracameral injection
A/C injection of 1.25 mg/0.05 mL bevacizumab
ProcedureIntravitreal injection
Vitreous injection of 1.25 mg/0.05 mL bevacizumab

What researchers measure

Primary outcomes

regression of nevolascularization
Amount of nevolascular of iris and angle regression
Time frame: 2 months

Secondary outcomes

IOP reduction
IOP reduction at 2-month visit compare to baseline
Time frame: 2 months
Injection complication
Hyphema, IOP spike
Time frame: 2 days

Study locations

1 of 1 sites recruiting

Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University
Hat Yai, Changwat Songkhla 90110, Thailand
- WEERAWAT KIDDEE, MD · Contact · kweerawat@hotmail.com · 66-81271-0644
Recruiting

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT03648814
Lead sponsor: Prince of Songkla University
Responsible party: Weerawat Kiddee (Assoc. Prof., Prince of Songkla University) — Principal investigator
First posted: Aug 27, 2018
Start date: Aug 1, 2018
Primary completion: Jul 1, 2026 (estimated)
Completion: Jul 1, 2026 (estimated)
Last update: Aug 21, 2025

Study contacts

Assoc.Prof.Weerawat Kiddee, MD

Contact

kweerawat@hotmail.com

+66874954626

Assoc.Prof.Weerawat Kiddee, MD

principal investigator · Prince of Songkla University

Oversight

Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Glaucoma, Neovascular→

Other studies from this sponsor

Prince of Songkla University

Start the discussion